Advertisement
AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

AJPH First Look, published online ahead of print Apr 26, 2005
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
AJPH.2004.039438v1
95/5/800    most recent
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Author home page(s):
Susan s Ellenberg
Mary A Foulkes
Karen Midthun
Karen l Goldenthal
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ellenberg, S. s
Right arrow Articles by Goldenthal, K. l
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ellenberg, S. s
Right arrow Articles by Goldenthal, K. l
©
American Journal of Public Health, 10.2105/AJPH.2004.039438

Public Health Matters

Evaluating the Safety of New Vaccines: Summary of a Workshop

Susan s Ellenberg 1*, Mary A Foulkes 1, Karen Midthun 1, Karen l Goldenthal 1

1 fda

* To whom correspondence should be addressed. E-mail: sellenbe{at}cceb.upenn.edu.


  Abstract

Public concerns about the safety of vaccines regularly arise. In November 2000, a workshop was convened by the U.S. Public Health Service agencies, including the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Health Resources and Services Administration (HRSA), to discuss appropriate methods for evaluating the safety of new vaccines. Workshop presentations addressed the current standards and approaches for new vaccine evaluation and post-licensure surveillance, as well as public views about vaccine safety and alternative approaches that could be considered. The advantages and disadvantages of conducting larger controlled trials prior to licensure and/or widespread use of a new vaccine were presented and discussed. This paper summarizes these presentations and discussion.

Key Words: Health Policy, Immunization/Vaccines, Statistics/Evaluation/Research




This article has been cited by other articles:


Home page
 AJPHHome page
M. R. Griffin, M. M. Braun, and K. J. Bart
What Should an Ideal Vaccine Postlicensure Safety System Be?
Am J Public Health, October 1, 2009; 99(S2): S345 - S350.
[Abstract] [Full Text] [PDF]

Home page
 Health Aff (Millwood)Home page
S. D. Reed, K. J. Anstrom, D. M. Seils, R. M. Califf, and K. A. Schulman
Use Of Larger Versus Smaller Drug-Safety Databases Before Regulatory Approval: The Trade-Offs
Health Aff., September 1, 2008; 27(5): w360 - w370.
[Abstract] [Full Text] [PDF]

Home page
 AJPHHome page
J. A. Berlin, S. C. Glasser, and S. S. Ellenberg
Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3
Am J Public Health, August 1, 2008; 98(8): 1366 - 1371.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
J. F Heyse, B. J Kuter, M. J Dallas, and P. Heaton for the RE
Evaluating the safety of a rotavirus vaccine: the REST of the story
Clinical Trials, April 1, 2008; 5(2): 131 - 139.
[Abstract] [PDF]

Home page
 JAMAHome page
S. W. Roush, T. V. Murphy, and and the Vaccine-Preventable Disease Table Working
Historical Comparisons of Morbidity and Mortality for Vaccine-Preventable Diseases in the United States
JAMA, November 14, 2007; 298(18): 2155 - 2163.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Public Health Association